CN1642415A - 可口的口服悬浮液及其制备方法 - Google Patents
可口的口服悬浮液及其制备方法 Download PDFInfo
- Publication number
- CN1642415A CN1642415A CNA038058405A CN03805840A CN1642415A CN 1642415 A CN1642415 A CN 1642415A CN A038058405 A CNA038058405 A CN A038058405A CN 03805840 A CN03805840 A CN 03805840A CN 1642415 A CN1642415 A CN 1642415A
- Authority
- CN
- China
- Prior art keywords
- medicine
- suspension
- regulator agent
- pharmaceutical composition
- drug
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
组分(优选) | 组分的范围mg | 组分的优选范围mg |
药物(Des-喹诺酮) | 10至600 | 12.7至508 |
pH调节剂(L-精氨酸) | 3至200 | 4.2至170 |
抗氧化剂(亚硫酸氢钠) | 0至20 | 0.4至14 |
悬浮剂(羧甲基纤维素) | 0至24 | 6至10 |
粉状助流剂(二氧化硅) | 0至100 | 20至60 |
防腐剂(羟苯甲酸甲酯) | 0至16 | 6至10 |
甜味剂(木糖醇)(冬瓜甜素) | 0至30000至400 | 2500至280050至300 |
香料和改味剂 | 0至200 | 10至100 |
实施例No. | 2 | 3 | 4 | 5 |
组分 | 10mg/5ml | 100mg/5ml | 200mg/5ml | 400mg/5ml |
Des-喹诺酮(优选) | 0.0127(10mg活性) | 0.1265(100mg活性) | 0.2540(200mg活性) | 0.5080(400mg活性) |
亚硫酸氢钠 | 0.0004 | 0.0035 | 0.0070 | 0.0140 |
二氧化硅 | 0.0200 | 0.0200 | 0.0600 | 0.0600 |
天冬甜素 | 0.0500 | 0.2000 | 0.3000 | 0.3000 |
L-精氨酸 | 0.0042 | 0.0420 | 0.0850 | 0.1700 |
羧甲基纤维素钠 | 0.0080 | 0.0080 | 0.0080 | 0.0080 |
羟苯甲酸甲酯 | 0.0080 | 0.0080 | 0.0080 | 0.0080 |
Magnasweet 100 | 0.0100 | 0.0180 | 0.0200 | 0.0220 |
天然特殊化合物 | 0.0300 | 0.0300 | 0.0300 | 0.0300 |
人工葡萄香料 | 0.0450 | 0.0450 | 0.0450 | 0.0450 |
木糖醇 | 2.8000 | 2.8000 | 2.5000 | 2.5000 |
净重 | 2.9883 | 3.301 | 3.317 | 3.665 |
Claims (21)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US36370402P | 2002-03-12 | 2002-03-12 | |
US60/363,704 | 2002-03-12 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1642415A true CN1642415A (zh) | 2005-07-20 |
CN100337630C CN100337630C (zh) | 2007-09-19 |
Family
ID=28041802
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB038058405A Expired - Fee Related CN100337630C (zh) | 2002-03-12 | 2003-03-06 | 可口的口服悬浮液及其制备方法 |
Country Status (16)
Country | Link |
---|---|
US (1) | US7175856B2 (zh) |
EP (1) | EP1482789A4 (zh) |
JP (1) | JP4619658B2 (zh) |
CN (1) | CN100337630C (zh) |
AR (1) | AR038947A1 (zh) |
AU (1) | AU2003220058B2 (zh) |
BR (1) | BR0308343A (zh) |
CA (1) | CA2478411C (zh) |
MX (1) | MXPA04008720A (zh) |
NO (1) | NO20043986L (zh) |
NZ (1) | NZ534746A (zh) |
PE (1) | PE20030885A1 (zh) |
PL (1) | PL212421B1 (zh) |
TW (1) | TW200304832A (zh) |
WO (1) | WO2003077842A2 (zh) |
ZA (1) | ZA200406585B (zh) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102397546A (zh) * | 2010-09-10 | 2012-04-04 | 广州自远生物科技有限公司 | 一种用于嗅觉或味觉敏感型动物的药物给药方法 |
CN102397552A (zh) * | 2010-09-10 | 2012-04-04 | 广州自远生物科技有限公司 | 一种含喹诺酮类的药物复合制剂及其制备方法和应用 |
CN107427505A (zh) * | 2015-02-25 | 2017-12-01 | 卫材R&D管理有限公司 | 用于抑制喹啉衍生物的苦味的方法 |
CN110151704A (zh) * | 2019-07-05 | 2019-08-23 | 华裕(无锡)制药有限公司 | 阿奇霉素干混悬剂的制备方法 |
CN111201013A (zh) * | 2017-10-13 | 2020-05-26 | 研究三角协会 | 硫酸羟基氯喹制剂及其制备和使用方法 |
US11186547B2 (en) | 2014-08-28 | 2021-11-30 | Eisai R&D Management Co., Ltd. | High-purity quinoline derivative and method for manufacturing same |
US11369623B2 (en) | 2015-06-16 | 2022-06-28 | Prism Pharma Co., Ltd. | Anticancer combination of a CBP/catenin inhibitor and an immune checkpoint inhibitor |
US11547705B2 (en) | 2015-03-04 | 2023-01-10 | Merck Sharp & Dohme Llc | Combination of a PD-1 antagonist and a VEGF-R/FGFR/RET tyrosine kinase inhibitor for treating cancer |
US11598776B2 (en) | 2011-06-03 | 2023-03-07 | Eisai R&D Management Co., Ltd. | Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE602005023193D1 (de) * | 2004-10-15 | 2010-10-07 | Suedzucker Ag | Verbessertes trommelcoating-verfahren |
US8653145B2 (en) * | 2005-09-22 | 2014-02-18 | Eaton Scientific Systems, Ltd. | Method for alleviating climacteric symptoms |
CA2627529A1 (en) | 2007-03-28 | 2008-09-28 | Apotex Technologies Inc. | Fluorinated derivatives of deferiprone |
US20100210604A1 (en) * | 2007-06-13 | 2010-08-19 | Meythaler Jay M | Zwitterion solution for low-volume therapeutic delivery |
WO2008157288A2 (en) * | 2007-06-13 | 2008-12-24 | Wayne State University Board Of Governors | A baclofen solution for low-volume therapeutic delivery |
JP5009707B2 (ja) * | 2007-07-10 | 2012-08-22 | 東和薬品株式会社 | 不快な味がマスキングされたキノロン系抗菌剤の経口投与用液剤 |
US7884227B2 (en) * | 2007-10-26 | 2011-02-08 | Navinta Llc | Felbamate with improved bulk density |
GB2470494B (en) * | 2008-01-17 | 2012-08-08 | Univ Holy Ghost Duquesne | Antiretroviral drug formulations for treatment of children exposed to HIV/AIDS |
SI2268282T1 (sl) * | 2008-04-25 | 2015-01-30 | Apotex Technologies Inc. | Tekoča farmacevtska oblika deferiprona s prijetnim okusom |
EP2343089A4 (en) | 2008-09-23 | 2013-05-01 | Jaer S A Lab | USE OF XYLITOL OR DERIVATIVES THEREOF FOR MASKING THE TASTE OF CHEMOTHERAPEUTIC MEDICAMENTS OF THE CHINOLO-N-NAPHTHYRIDONE-CARBOXYLIC ACID GROUP FOR PIG DICULTINATION |
ES2351643B1 (es) * | 2009-07-27 | 2011-09-15 | Laboratorio Jaer,S.A. | Utilización de xilitol o sus derivados para el enmascaramiento gustativo de quimioterápicos del grupo del ácido quinolon-o-naftiridoncarboxílico administrados en alimentos destinados a ganado porcino. |
ES2335334B1 (es) * | 2008-09-23 | 2011-02-09 | Laboratorio Jaer, S.A. | Utilizacion del xilitol para el enmascaramiento gustativo de amargantes en alimentos para animales. |
BR112012000079A2 (pt) | 2009-07-03 | 2017-07-25 | Apotex Tech Inc | derivados fluorados de 3-hidroxipiridin-4-onas |
US20110236494A1 (en) * | 2010-03-04 | 2011-09-29 | Ranbaxy Laboratories Limited | Ciprofloxacin oral suspension |
GB201006218D0 (en) * | 2010-04-14 | 2010-06-02 | Ayanda As | Composition |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE8103843L (sv) | 1981-06-18 | 1982-12-19 | Astra Laekemedel Ab | Farmaceutisk mixtur |
CA1239349A (en) * | 1983-10-10 | 1988-07-19 | Eberhard F. Gottwald | Pharmaceutical composition containing cimetidine |
JPS61180771A (ja) * | 1985-01-05 | 1986-08-13 | バイエル・アクチエンゲゼルシヤフト | 安定な抗バクテリア剤水溶液 |
GB8623557D0 (en) * | 1986-10-01 | 1986-11-05 | Boots Co Plc | Therapeutic agents |
NL193682C (nl) * | 1987-05-14 | 2000-07-04 | Glaxo Group Ltd | Beklede cefuroximaxetilsamenstelling. |
DE3719764A1 (de) * | 1987-06-13 | 1988-12-22 | Bayer Ag | Ionenaustauscherharze beladen mit chinoloncarbonsaeurederivaten, ihre herstellung und verwendung |
DE3902079A1 (de) * | 1988-04-15 | 1989-10-26 | Bayer Ag | I.m. injektionsformen von gyrase-inhibitoren |
DE3831514A1 (de) * | 1988-09-16 | 1990-03-22 | Bayer Ag | Ph-neutrale waessrige loesungen von chinoloncarbonsaeuren |
US4975465A (en) * | 1989-03-28 | 1990-12-04 | American Home Products Corporation | Orally administrable ibuprofen compositions |
US5262179A (en) * | 1989-09-13 | 1993-11-16 | Nicholas Kiwi Pty Ltd. | Non-effervescent ibuprofen compositions |
IE63986B1 (en) * | 1989-12-30 | 1995-06-28 | Akzo Nv | Pharmaceutical preparation for oral administration in fluid form |
IT1246383B (it) * | 1990-04-17 | 1994-11-18 | Eurand Int | Metodo per il mascheramento del sapore di farmaci |
JP3184239B2 (ja) * | 1991-04-25 | 2001-07-09 | 京都薬品工業株式会社 | 矯味経口用医薬組成物 |
DE4200821A1 (de) * | 1992-01-15 | 1993-07-22 | Bayer Ag | Geschmacksmaskierte pharmazeutische mittel |
US5272137A (en) * | 1992-02-14 | 1993-12-21 | Mcneil-Pfc, Inc. | Aqueous pharmaceutical suspension for pharmaceutical actives |
JPH05309314A (ja) * | 1992-05-07 | 1993-11-22 | Sumitomo Pharmaceut Co Ltd | コーティング方法 |
ZA945944B (en) * | 1993-08-13 | 1996-02-08 | Eurand America Inc | Procedure for encapsulating nsaids |
ATE245638T1 (de) * | 1994-08-12 | 2003-08-15 | Toyama Chemical Co Ltd | Neue chinolon- oder naphthyridoncarbonsäurederivate oder deren salze |
RU2141821C1 (ru) * | 1994-10-14 | 1999-11-27 | Жансен Фармасетика Н.В. | Водная суспензия сабелюзола для орального применения и способ ее изготовления |
US5738875A (en) * | 1994-10-28 | 1998-04-14 | R.P. Scherer Corporation | Process for preparing solid pharmaceutical dosage forms |
ATE216576T1 (de) * | 1995-02-08 | 2002-05-15 | Yamanouchi Europ Bv | Vehrfahren zur herstellung von beta-lactam antibiotikum enthaltenden oralen dosisformen |
US5972379A (en) * | 1995-02-14 | 1999-10-26 | Sequus Pharmaceuticals, Inc. | Liposome composition and method for administering a quinolone |
WO1997029102A1 (fr) * | 1996-02-09 | 1997-08-14 | Toyama Chemical Co., Ltd. | Derives de l'acide quinolonecarboxylique et leurs sels |
AUPN969796A0 (en) * | 1996-05-07 | 1996-05-30 | F.H. Faulding & Co. Limited | Taste masked liquid suspensions |
JP3424038B2 (ja) * | 1996-06-17 | 2003-07-07 | 株式会社日本点眼薬研究所 | 合成抗菌剤水性組成物 |
CZ20014230A3 (cs) * | 1999-05-27 | 2002-08-14 | Pfizer Products Inc. | Suspense ziprasidonu |
US6239141B1 (en) * | 1999-06-04 | 2001-05-29 | Pfizer Inc. | Trovafloxacin oral suspensions |
-
2003
- 2003-03-06 CA CA2478411A patent/CA2478411C/en not_active Expired - Fee Related
- 2003-03-06 WO PCT/US2003/006855 patent/WO2003077842A2/en active Application Filing
- 2003-03-06 NZ NZ534746A patent/NZ534746A/en not_active IP Right Cessation
- 2003-03-06 EP EP03716347A patent/EP1482789A4/en not_active Withdrawn
- 2003-03-06 PL PL373570A patent/PL212421B1/pl unknown
- 2003-03-06 CN CNB038058405A patent/CN100337630C/zh not_active Expired - Fee Related
- 2003-03-06 AU AU2003220058A patent/AU2003220058B2/en not_active Ceased
- 2003-03-06 BR BRPI0308343-8A patent/BR0308343A/pt not_active IP Right Cessation
- 2003-03-06 MX MXPA04008720A patent/MXPA04008720A/es active IP Right Grant
- 2003-03-06 JP JP2003575896A patent/JP4619658B2/ja not_active Expired - Fee Related
- 2003-03-11 US US10/386,199 patent/US7175856B2/en not_active Expired - Fee Related
- 2003-03-11 TW TW092105244A patent/TW200304832A/zh unknown
- 2003-03-12 PE PE2003000249A patent/PE20030885A1/es not_active Application Discontinuation
- 2003-03-12 AR ARP030100851A patent/AR038947A1/es not_active Application Discontinuation
-
2004
- 2004-08-18 ZA ZA2004/06585A patent/ZA200406585B/en unknown
- 2004-09-23 NO NO20043986A patent/NO20043986L/no not_active Application Discontinuation
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102397546A (zh) * | 2010-09-10 | 2012-04-04 | 广州自远生物科技有限公司 | 一种用于嗅觉或味觉敏感型动物的药物给药方法 |
CN102397552A (zh) * | 2010-09-10 | 2012-04-04 | 广州自远生物科技有限公司 | 一种含喹诺酮类的药物复合制剂及其制备方法和应用 |
CN102397552B (zh) * | 2010-09-10 | 2016-06-08 | 广州自远生物科技有限公司 | 一种含喹诺酮类的药物复合制剂及其制备方法和应用 |
US11598776B2 (en) | 2011-06-03 | 2023-03-07 | Eisai R&D Management Co., Ltd. | Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds |
US11186547B2 (en) | 2014-08-28 | 2021-11-30 | Eisai R&D Management Co., Ltd. | High-purity quinoline derivative and method for manufacturing same |
CN107427505A (zh) * | 2015-02-25 | 2017-12-01 | 卫材R&D管理有限公司 | 用于抑制喹啉衍生物的苦味的方法 |
US11090386B2 (en) | 2015-02-25 | 2021-08-17 | Eisai R&D Management Co., Ltd. | Method for suppressing bitterness of quinoline derivative |
US11547705B2 (en) | 2015-03-04 | 2023-01-10 | Merck Sharp & Dohme Llc | Combination of a PD-1 antagonist and a VEGF-R/FGFR/RET tyrosine kinase inhibitor for treating cancer |
US12083112B2 (en) | 2015-03-04 | 2024-09-10 | Eisai R&D Management Co., Ltd. | Combination of a PD-1 antagonist and a VEGFR/FGFR/RET tyrosine kinase inhibitor for treating cancer |
US11369623B2 (en) | 2015-06-16 | 2022-06-28 | Prism Pharma Co., Ltd. | Anticancer combination of a CBP/catenin inhibitor and an immune checkpoint inhibitor |
CN111201013A (zh) * | 2017-10-13 | 2020-05-26 | 研究三角协会 | 硫酸羟基氯喹制剂及其制备和使用方法 |
CN110151704A (zh) * | 2019-07-05 | 2019-08-23 | 华裕(无锡)制药有限公司 | 阿奇霉素干混悬剂的制备方法 |
Also Published As
Publication number | Publication date |
---|---|
US20030187019A1 (en) | 2003-10-02 |
MXPA04008720A (es) | 2004-12-06 |
CN100337630C (zh) | 2007-09-19 |
NZ534746A (en) | 2006-06-30 |
CA2478411A1 (en) | 2003-09-25 |
BR0308343A (pt) | 2006-06-06 |
JP2006504620A (ja) | 2006-02-09 |
EP1482789A2 (en) | 2004-12-08 |
TW200304832A (en) | 2003-10-16 |
US7175856B2 (en) | 2007-02-13 |
AU2003220058B2 (en) | 2008-05-01 |
PE20030885A1 (es) | 2003-10-23 |
EP1482789A4 (en) | 2010-12-29 |
PL212421B1 (pl) | 2012-09-28 |
NO20043986L (no) | 2004-09-23 |
ZA200406585B (en) | 2005-11-30 |
WO2003077842A3 (en) | 2004-03-25 |
CA2478411C (en) | 2010-09-28 |
WO2003077842A2 (en) | 2003-09-25 |
JP4619658B2 (ja) | 2011-01-26 |
AU2003220058A1 (en) | 2003-09-29 |
AR038947A1 (es) | 2005-02-02 |
PL373570A1 (en) | 2005-09-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN100337630C (zh) | 可口的口服悬浮液及其制备方法 | |
TWI763881B (zh) | 帕博西里之固態劑型 | |
JP6092629B2 (ja) | リファキシミン使用準備済懸濁液 | |
EP1194153B1 (en) | Taste masked pharmaceutical liquid formulations | |
US20040197402A1 (en) | Oxcarbazepine dosage forms | |
JP2005511588A (ja) | ニコチン渇望の減少または予防に有用な経口放出制御形態 | |
JPS63112514A (ja) | スプレードライしたアセトアミノフェン | |
JP2019196367A (ja) | アプレピタント経口液体製剤 | |
US20070264332A1 (en) | Sustained Release Pharmaceutical Formulation | |
FR2832635A1 (fr) | Composition a base de cefuroxime axetil et son utilisation | |
JP2009506067A5 (zh) | ||
EP1492507A2 (en) | Clarithromycin formulations having improved bioavailability | |
WO2015142178A1 (en) | Bile acid composition with enhanced solubility | |
KR100963051B1 (ko) | 입자크기가 조절된 술포데히드로아비에트산을 함유한쓴맛이 저감된 경구용 액상 조성물 | |
CA2270306C (en) | Pharmaceutical compositions comprising co-micronized fenofibrate | |
JP2004242508A (ja) | コエンザイムq10および水溶性ビタミンを含有する食品 | |
JP2003221330A (ja) | 分岐鎖アミノ酸を含有するゼリー剤 | |
US20070286901A1 (en) | Novel Pharmaceutical Formulation of Cefixime for Enhanced Bioavailability | |
WO2020150460A1 (en) | Micronized aspirin formulation | |
GB2624171A (en) | An orally disintegrating tablet containing atorvastatin and process of preparing the same | |
WO2009056256A1 (en) | Use of megestrol acetate having improved solubility for the treatment of cancer cachexia | |
AU2002302888A1 (en) | Oxcarbazepine dosage forms |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: TOYAMA CHEMICAL CO., LTD. Free format text: FORMER OWNER: BRISTOL-MYERS SQUIBB COMPANY Effective date: 20100908 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: NEW JERSEY, UNITED STATES TO: TOKYO TO, JAPAN |
|
TR01 | Transfer of patent right |
Effective date of registration: 20100908 Address after: Tokyo, Japan, Japan Patentee after: Toyama Chemical Co., Ltd. Address before: new jersey Patentee before: Bristol-Myers Squibb Co. |
|
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20070919 Termination date: 20160306 |
|
CF01 | Termination of patent right due to non-payment of annual fee |